Investigating Rational Combination Therapies for Triple-Negative Breast Cancer
研究三阴性乳腺癌的合理联合疗法
基本信息
- 批准号:10367060
- 负责人:
- 金额:$ 34.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineCell DeathCell SurvivalCellsChemotherapy and/or radiationClinicalClinical InvestigatorCollaborationsCollectionCombined Modality TherapyDiseaseDisease ProgressionDrug CombinationsDrug ScreeningDrug SynergismEpidermal Growth Factor ReceptorEstrogen ReceptorsExcisionExperimental ModelsFDA approvedFamilyGoalsGrowthHumanImpairmentIn VitroLifeLiquid substanceMalignant NeoplasmsMammary NeoplasmsMultiple MyelomaOncogenicOncoproteinsOperative Surgical ProceduresOutcomeOutcomes ResearchOxidative StressPIM1 genePathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhasePhosphotransferasesPre-Clinical ModelProgesterone ReceptorsProteasome InhibitionProteasome InhibitorProtein IsoformsProteinsReactive Oxygen SpeciesRecurrenceReportingResearchResistanceSamplingSavingsSolidSolid NeoplasmStressTestingTranslatingUp-RegulationValidationXenograft Modelantitumor effectbasebiological adaptation to stresscancer stem cellcancer subtypescancer typeclinical developmentclinically relevantcytotoxicitydrug testingdruggable targetearly experienceefficacy evaluationefficacy studyhuman modelin vivoinhibitorkinase inhibitormalignant breast neoplasmmisfolded proteinmolecular targeted therapiesmortalitymouse modelmulticatalytic endopeptidase complexneoplastic cellnoveloverexpressionoxidative damagepre-clinicalproteotoxicityproto-oncogene protein pimrational designreceptorresearch clinical testingresistance mechanismscreeningsmall molecule inhibitorstandard of carestem-like celltargeted treatmenttherapy resistanttooltranscription factortreatment strategytriple-negative invasive breast carcinomatumortumor growthtumor xenograft
项目摘要
PROJECT SUMMARY/ABSTRACT
Triple-negative breast cancer (TNBC) refers to a collection of heterogeneous breast tumors that lack expression
of immediately druggable molecules, such as the estrogen and progesterone receptors and human epidermal
growth factor receptor 2. No targeted therapy is currently approved for the vast majority of TNBC patients. TNBC
patients who have received the current standard of care, consisting of chemotherapy, radiation, and surgery,
often experience early tumor recurrence and a significantly worse mortality rate. Therefore, it is critical to identify
and validate clinically viable, life-saving targeted therapies for patients with TNBC. We previously reported that
the oncogenic MYC pathways were activated in ~50% of TNBC cases compared with non-TNBC cases and that
MYC levels were associated with poor outcomes among TNBC patients. Unfortunately, clinical development of
inhibitors that directly target MYC activity has remained challenging. To overcome this challenge, we previously
took an alternative approach known as the synthetic lethal screening approach to identify readily druggable
targets required for MYC-driven tumor viability but that are not essential in non-tumor cells. Our screen identified
the PIM family of kinases, which is composed of the closely related nonessential kinase isoforms PIM1, -2, and
-3 (PIM hereafter), as a promising target in MYC-driven TNBC. We found that PIM expression was elevated in
triple-negative (TN) tumors in clinical samples and was associated with poor patient outcomes. Clinically relevant
pan-PIM inhibitors showed activity in various experimental models of TNBC. However, our single-agent efficacy
studies using preclinical PIM inhibitors showed that although PIM inhibition significantly slowed the growth of TN
tumors, it induced only modest in vivo tumor cell death and regression, suggesting the need for combination
therapies. We have taken robust drug screening approaches and have unexpectedly found that the drug
combination that targets PIM kinases and the proteasome can acutely induce toxic levels of proteotoxic stress
selectively in MYC-overexpressing TNBC cells. Mechanistically, our preliminary observations indicate that PIM
inhibition, which elevates the levels of reactive oxygen species, when combined with proteasome inhibition,
overwhelms the capacity of TNBC cells to continuously degrade damaged proteins, resulting in proteotoxic crisis.
Thus, our observations raise the possibility—and our study will test the hypothesis—that PIM inhibition
represents a unique and clinically viable tool to sensitize TNBC tumors to proteasome inhibition. The successful
execution of this research will allow for the identification and interrogation of clinically exploitable vulnerabilities
in MYC-driven solid-cancer types such as TNBC. The outcomes of this research could also encourage the FDA-
approved proteasome inhibitors (e.g., carfilzomib), which have not been successfully used outside of liquid tumor
types, to be rapidly evaluated in combination with pan-PIM kinase inhibitors in early-stage MYC-driven solid-
tumor trials.
项目概要/摘要
三阴性乳腺癌(TNBC)是指缺乏表达的异质乳腺肿瘤的集合
立即可成药的分子,例如雌激素和孕激素受体以及人类表皮
生长因子受体2。目前还没有批准针对绝大多数TNBC患者的靶向治疗。三全国广播公司
接受当前标准护理(包括化疗、放疗和手术)的患者,
经常经历早期肿瘤复发和显着更差的死亡率。因此,识别至关重要
并验证针对 TNBC 患者的临床可行、挽救生命的靶向治疗。我们之前报道过
与非 TNBC 病例相比,大约 50% 的 TNBC 病例中致癌 MYC 通路被激活
MYC 水平与 TNBC 患者的不良预后相关。不幸的是,临床发展
直接靶向 MYC 活性的抑制剂仍然具有挑战性。为了克服这一挑战,我们之前
采用了一种称为合成致死筛选方法的替代方法来识别易于药物化的方法
MYC 驱动的肿瘤活力所需的靶标,但对于非肿瘤细胞来说并不是必需的。我们的屏幕已识别
PIM 激酶家族,由密切相关的非必需激酶亚型 PIM1、-2 和
-3(以下简称 PIM),作为 MYC 驱动的 TNBC 中一个有前途的目标。我们发现 PIM 表达升高
临床样本中存在三阴性(TN)肿瘤,并与患者预后不良相关。临床相关
pan-PIM 抑制剂在 TNBC 的各种实验模型中显示出活性。然而,我们的单药疗效
使用临床前 PIM 抑制剂的研究表明,尽管 PIM 抑制显着减缓了 TN 的生长
肿瘤,它仅诱导适度的体内肿瘤细胞死亡和消退,表明需要联合使用
疗法。我们采取了强有力的药物筛选方法,并意外地发现该药物
针对 PIM 激酶和蛋白酶体的组合可以急性诱导毒性水平的蛋白毒性应激
选择性地作用于 MYC 过表达的 TNBC 细胞。从机制上讲,我们的初步观察表明 PIM
当与蛋白酶体抑制相结合时,抑制作用会提高活性氧的水平,
压倒了 TNBC 细胞持续降解受损蛋白质的能力,导致蛋白毒性危机。
因此,我们的观察提出了一种可能性——并且我们的研究将检验这一假设——PIM 抑制
代表了一种独特且临床上可行的工具,可以使 TNBC 肿瘤对蛋白酶体抑制敏感。成功者
这项研究的执行将允许识别和询问临床可利用的漏洞
MYC 驱动的实体癌类型,如 TNBC。这项研究的结果也可能鼓励 FDA——
已批准的蛋白酶体抑制剂(例如卡非佐米),但尚未成功用于液体肿瘤之外
类型,与早期 MYC 驱动的固体-泛 PIM 激酶抑制剂联合进行快速评估
肿瘤试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dai Horiuchi其他文献
Dai Horiuchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dai Horiuchi', 18)}}的其他基金
Investigating Rational Combination Therapies for Triple-Negative Breast Cancer
研究三阴性乳腺癌的合理联合疗法
- 批准号:
10543989 - 财政年份:2022
- 资助金额:
$ 34.35万 - 项目类别:
Exploiting synthetic-lethal interactions to target triple-negative breast cancers
利用合成致死相互作用来靶向三阴性乳腺癌
- 批准号:
9269527 - 财政年份:2015
- 资助金额:
$ 34.35万 - 项目类别:
Exploiting synthetic-lethal interactions to target triple-negative breast cancers
利用合成致死相互作用来靶向三阴性乳腺癌
- 批准号:
9070742 - 财政年份:2015
- 资助金额:
$ 34.35万 - 项目类别:
Exploiting synthetic-lethal interactions to target triple-negative breast cancers
利用合成致死相互作用来靶向三阴性乳腺癌
- 批准号:
8487128 - 财政年份:2013
- 资助金额:
$ 34.35万 - 项目类别:
Exploiting synthetic-lethal interactions to target triple-negative breast cancers
利用合成致死相互作用来靶向三阴性乳腺癌
- 批准号:
8639510 - 财政年份:2013
- 资助金额:
$ 34.35万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 34.35万 - 项目类别:
Research Grant














{{item.name}}会员




